As reported by The Independent, The National Institute for Health and Clinical Excellence (NICE) has recommended Novartis’ MS drug, Gilenya to the National Health Service (NHS).
NICE is in the process of drafting guidance to the NHS recommending that Gilenya is used to treat those patients who have experienced an unchanged or increased relapse rate or have ongoing severe relapses (when compared to the previous year). It is estimated that the new MS drug help 3,000 patients in the UK.
What is MS?
Multiple Sclerosis is caused when the patients white blood cells attack the coatings of the nerve cells. This prevents messages from the brain travelling to other parts of the body. The damage to the nerve cells causes patients to experience symptoms such as numbness, tingling, blurred vision, muscle weakeness and balance problems.
How does Gilenya help?
The new MS drug, Gilenya helps by preventing the white blood cells from attacking the nerve cells in the train and spinal cord.
The MS drug is helpful for those patients with relapsing-remitting multiple sclerosis (RRMS), and has been shown to reduce the number of relapses these candidates experience.